comparemela.com
Latest Breaking News On - Flexibility for pivotal development - Page 1 : comparemela.com
Viridian Therapeutics Announces Positive Clinical Data in Healthy Volunteer Study and Selects VRDN-003 as Potential Best-in-Class Subcutaneous anti-IGF-1R Program with Extended Half-Life for Pivotal Development in Thyroid Eye Disease
- VRDN-003 clinical data exceeded expectations with extended half-life of 40-50 days, 4-5x longer than VRDN-001, supporting a potential best-in-class, low-volume, less frequent, self-administered.
United-states
Waltham
Massachusetts
Steve-mahoney
Tom-ciulla
Development-officer
Viridian-therapeutics-inc
Nasdaq
Exchange-commission
Flexibility-for-pivotal-development
Neither-the-company
Viridian-therapeutics
vimarsana © 2020. All Rights Reserved.